BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 30 pre-split shares.

巴尔的摩--（商业新闻短讯）--MyMD Pharmaceuticals，Inc.®（纳斯达克：MyMD）（“MyMD”或“该公司”），一家临床阶段的生物制药公司，致力于开发与年龄相关的疾病，自身免疫和炎症状况的新疗法，今天宣布，它打算对其普通股进行反向股票分割，分割后的股票与分割前的30股股票的比例为1。

The reverse stock split will become effective at 4:05 p.m. Eastern Standard Time on Wednesday, February 14, 2024. MyMD’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol MYMD and will begin trading on a split-adjusted basis when the market opens on Thursday, February 15, 2024.

反向股票分割将于2024年2月14日星期三东部标准时间下午4:05生效。MyMD的普通股将继续在纳斯达克资本市场上以MyMD的符号进行交易，并将在2024年2月15日（星期四）开市时以分割调整的方式开始交易。

The new CUSIP number for MyMD’s common stock following the reverse stock split will be 62856X201..

反向股票分割后，MyMD普通股的新CUSIP编号将为62856X201。。

At the effective time of the reverse stock split, every 30 shares of MyMD’s issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. Simultaneously therewith, the number of shares of common stock that the Company shall have authority to issue will be reduced by a factor of 30 from 500,000,000 shares to 16,666,666 shares.

在反向股票分割生效时，每30股MyMD已发行和流通的普通股将自动转换为一股已发行和流通的普通股，而每股面值没有任何变化。同时，公司有权发行的普通股数量将减少30倍，从500000000股减少到16666666股。

Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1‑for-30 reverse stock split. It is not necessary for stockholders holding shares of the Company’s common stock in certificated form to exchange their existing stock certificates for new stock certificates of the Company in connection with the reverse stock split, although stockholders may do so if they wish..

通过经纪账户持有股份的股东将自动调整其股份，以反映30分之一的反向股票分割。持有公司普通股证书形式股份的股东无需将其现有股票换成与反向股票分割有关的公司新股票，尽管股东可以这样做。。

The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. Any fractional share of a stockholder resulting from the reverse stock split will be rounded up to the nearest whole number of shares.

反向股票分割将统一影响所有股东，并且不会改变任何股东在公司股权中的百分比权益，除非反向股票分割会导致股东拥有零散股份。反向股票分割产生的股东的任何部分股份将被四舍五入到最接近的股份总数。

The reverse stock split will reduce the number of shares of MyMD’s common stock outstanding from 62,749,125 shares to approximately 2,091,638 shares, subject to adjustment for the rounding up of fractional shares. Proportional adjustments will be made to the number of shares of MyMD’s common stock issuable upon exercise or conversion of MyMD’s equity awards, convertible preferred stock and warrants, as well as the applicable exercise or conversion price.

反向股票分割将使MyMD已发行普通股的股数从62749125股减少到约2091638股，但需对部分股票进行四舍五入调整。在行使或转换MyMD的股权奖励、可转换优先股和认股权证时，将按比例调整MyMD可发行的普通股股数，以及适用的行使或转换价格。

Stockholders with shares in brokerage accounts should direct any questions concerning the reverse stock split to their broker; all other stockholders may direct questions to the Company’s transfer agent, Securities Transfer Corporation, via email at issuerservices@stctransfer.com or phone at (469) 633-0101..

持有经纪账户股份的股东应将有关反向股票分割的任何问题告知其经纪人；所有其他股东可通过电子邮件向公司的转让代理人证券转让公司提出问题issuerservices@stctransfer.com或致电（469）633-0101。。

About MyMD Pharmaceuticals, Inc.

关于MyMD Pharmaceuticals，Inc。

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines.

MyMD Pharmaceuticals，Inc.（纳斯达克：MyMD）是一家致力于延长健康寿命的临床阶段制药公司，专注于开发两种新型治疗平台，以治疗疾病的原因，而不仅仅是解决症状。MYMD-1是一种基于临床阶段小分子的药物平台，可调节免疫系统以控制驱动慢性炎症的TNF-α和其他促炎细胞信号细胞因子。

MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs.

正在开发MYMD-1以延缓衰老，延长寿命和治疗自身免疫性疾病。该公司的第二个药物平台Supera CBD正在开发中，用于治疗慢性疼痛、成瘾和癫痫。Supera CBD是大麻二酚（CBD）的一种新型合成衍生物，正在开发中，以应对和改善快速增长的CBD市场，其中包括FDA批准的药物和目前未作为药物监管的CBD产品。

For more information, visit www.mymd.com..

For more information, visit www.mymd.com..

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性声明的警示声明

This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements.

本新闻稿可能包含前瞻性声明。这些前瞻性陈述涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致实际结果、绩效或成就与任何预期的未来结果、绩效或成就存在重大差异。

Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “may,” “plan,” “will,” “would’’ and other similar expressions are intended to identify these forward-looking statements.

前瞻性声明仅在发布之日起生效，MyMD及其附属公司均无义务更新前瞻性声明。诸如“预期”、“相信”、“可能”、“估计”、“预期”、“可能”、“计划”、“将”、“将”等词语以及其他类似的表达方式旨在识别这些前瞻性陈述。

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the effect that the reverse stock split may have on the price of MyMD’s common stock; MyMD’s ability to regain and maintain compliance with the Nasdaq Stock Market’s listing standards; the timing of, and MyMD’s ability to, obtain and maintain regulatory approvals for clinical trials of MyMD’s pharmaceutical candidates; the timing and results of MyMD’s planned clinical trials for its pharmaceutical candidates; the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMD’s ability to retain and attract senior management and other key employees; MyMD’s ability to quickly and effectively respond to new technological developments; MyMD’s ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMD’s proprietary righ.

可能导致实际结果与此类前瞻性声明所示结果存在重大差异的重要因素包括但不限于：反向股票分割可能对MyMD普通股价格产生的影响；MyMD恢复并保持符合纳斯达克股票市场上市标准的能力；MyMD获得和维持MyMD候选药物临床试验监管批准的时间和能力；MyMD计划对其候选药物进行临床试验的时间和结果；MyMD为其候选药物所需的资金数额；竞争程度提高；一般政治、经济或监管条件以及MyMD运营所在市场的变化；MyMD留住和吸引高级管理人员和其他关键员工的能力；MyMD快速有效应对新技术发展的能力；MyMD有能力保护其商业秘密或其他专有权利，在不侵犯他人专有权利的情况下运营，并防止他人侵犯MyMD的专有权利。